Introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in the United States in 2000 led to dramatic reductions in the incidence of invasive pneumococcal disease (IPD) among children and adults [1] [2] [3] . Because most of the antimicrobial-nonsusceptible pneumococcal strains during the prevaccine period were covered by PCV7, rates of IPD caused by nonsusceptible pneumococci also decreased after vaccine introduction [4] . In the United States, the incidence of IPD caused by serotype 19A increased after the introduction of PCV7 [5] [6] [7] . A recent study showed the important association between serotype 19A and antimicrobial resistance and demonstrated that increased rates of IPD due to serotype 19A and of nonsusceptibility among 19A isolates were caused by new clonal types of serotype 19A [5] . Although serotype 19A is a member of the same serogroup as the PCV7 serotype 19F, PCV7-induced antibodies do not provide cross-protection against serotype 19A [8, 9] , nor does PCV7 protect against IPD caused by serotype 19A [10, 11] . Among pneumococcal isolates recovered from the respiratory tract, the proportion that are antibiotic-resistant serotype 19A has also increased significantly [12, 13] .
There are at least 3 reasons why serotype 19A has emerged since PCV7 introduction. First, expansion of a single preexisting clone of serotype 19A suggests that this clone has an advantage over other clones of serotype 19A. Second, 1 new clone of serotype 19A might have been introduced into a population [14] . Third, successful clones previously associated with other serotypes might have undergone a recombinational switch to serotype 19A. We explored these possible explanations by obtaining a detailed snapshot of the genetic structure of this rapidly evolving serotype through multilocus sequence typing (MLST) of invasive isolates collected during 2005 from patients of all ages and comparing this information with MLST data obtained before and after PCV7 introduction.
PATIENTS, MATERIALS, AND METHODS

Surveillance.
A case of IPD was defined as detection of pneumococci in a sample from a normally sterile site of an individual in the surveillance population of the Centers for Disease Control and Prevention's (CDC's) Active Bacterial Core surveillance (ABCs) system [4, 15] . The trend over time in the incidence of IPD caused by serotype 19A was evaluated by comparing rates in 2005 to rates during 1998 -1999 (defined as the prevaccine baseline period) separately for areas under continuous surveillance (i.e., areas under surveillance throughout the study period) and for all areas, including those added to the surveillance system after 1998. Areas under continuous surveillance included all of Connecticut and selected counties in California, Georgia, Maryland, Minnesota, New York, Oregon, and Tennessee. The total population in 2005 for the areas under continuous surveillance was 18,484,400 persons (1,259,400 of whom were children Ͻ5 years old) according to 2005 Serotyping. Isolates were serotyped by the latex agglutination test and confirmed by the Quellung reaction.
Antimicrobial susceptibility testing. Minimum inhibitory concentrations (MICs) were determined by the Clinical and Laboratory Standards Institute (CLSI) microdilution method. Isolates recovered in 2005 were tested for susceptibility to penicillin, amoxicillin, cefotaxime, ceftriaxone, cefuroxime, meropenem, chloramphenicol, tetracycline, clindamycin, erythromycin, linezolid, rifampin, ciprofloxacin, levofloxacin, telithromycin, quinupristin-dalfopristin, vancomycin, and trimethoprim-sulfamethoxazole. MICs were interpreted using CLSI guidelines [16] .
MLST. MLST was performed as described elsewhere [17] , with the following exceptions. Our primers differed in that the 5' end (available at: http://www.cdc.gov/ncidod/biotech/strep/ strepindex.htm) was 30 -80 bases upstream of each defined MLST locus, which improved the sequence quality at the ends. Unless new alleles were encountered, sequences were usually obtained on the forward strand only. Two different base callers (Applied Biosystems 3100 base caller and Phred [available at: http://www.phrap.org/consed/consed.html#howToGet]) were used to avoid mistaken allele assignments. The Basic Local Assignment Software Tool downloaded from the National Center for Biotechnology Information (available at: http://www.ncbi .nlm.nih.gov/blast/Blast.cgi), together with MLST database sequences downloaded from the pneumococcal database [18] , were used with a World Wide Web interface to supply the best hit in a tabular format for quick identification of the query. Sequences without perfect matches to known alleles were resolved visually, or reactions were repeated. When unusual serotypesequence type associations were found, the serotype was verified by means of polymerase chain reaction [19] and the same chromosomal template used for MLST. Key MLST alleles highly associated with sequence types involved in unusual serotype-sequence type combinations were reamplified and resequenced. When single or double locus variants of known sequence types were discovered, the variant loci were reamplified and resequenced for verification of results.
Trace files for 18 new MLST alleles and 38 new MLST profiles were submitted to the Multi Locus Sequence Typing S. pneumoniae database for designations [20] . Clonal complexes were assigned, using our serotype 19A MLST data with the eBURST algorithm [21] and MLST software [20] . Clonal complexes consisted primarily of sequence types that shared 6 of 7 alleles with at least 1 other sequence type in the complex. Six clonal complexes additionally included 1-2 MLST profiles that shared 4 -5 of the 7 MLST alleles.
Statistical analysis. Data were analyzed with SAS, version 9.1 (SAS Institute), and Epi Info, version 6.04b (Centers for Disease Control and Prevention). Annual incidence rates were calculated for 1998 -2005, using population estimates from the US Census Bureau for each calendar year. To calculate serotypespecific incidence rates, cases with missing serotype information were redistributed by age and race under the assumption that the frequency was the same as that for cases with serotype information. Trends in rates of disease were evaluated by comparing rates in 2005 to the average of rates during 1998 -1999, using the 2 test; 95% confidence intervals (CIs) were calculated. Trends in proportions of isolates nonsusceptible or resistant to antimicrobials were calculated using the 2 test for trend. A P value of Ͻ.05 was considered statistically significant.
GenBank accession numbers. Segments (984 -1558 bases) of pbp1A and pbp2X genes encoding penicillin binding domains and flanking regions representing identical segments from 2 ST236 serotype 19A isolates were submitted to GenBank and received accession numbers EU043519 and EU043520, respectively. Corresponding segments of pbp1A and pbp2X from reference strain Taiwan 19F -14 submitted to GenBank received accession numbers EU043521 and EU043522, respectively. figure 2B ).
RESULTS
Trends in IPD.
Trends in antibiotic resistance among individual serotypes. Although the number of isolates that were penicillin nonsusceptible (defined as a penicillin MIC of 0.12 g/mL) decreased during 1998 -2005, serotype 19A strains accounted for an increasing proportion of nonsusceptible strains. Of the 1985 invasive isolates recovered from children aged Ͻ5 years during 1998 -1999, a total of 271 (13.7%) were intermediately susceptible to penicillin (defined as an MIC of 0.12-1 g/mL), and 441 (22.2%) were resistant (defined as an MIC of 2 g/mL). Of the 712 penicillin- [5, 24] . eBURST analysis of sequence types limited to this study predicted that ST320 was the founder of this type 19A complex (figure 4).
Ten sequence types were suggestive of recent capsular switch events in which isolates of non-19A serotypes served as recipients of serotype 19A capsular biosynthetic genes. These 10 sequence types have not been previously reported among serotype 19A strains, including ST695 and ST899, both of which were previously associated solely with serotype 4 isolates (figure 4). ST695 is the single most frequent ST observed among invasive serotype 4 isolates recovered in the United States [23, 24] . It is interesting that, of the 32 ST695 isolates, 30 were restricted to northeastern ABCs sites (i.e., New York, Maryland, and Connecticut), which is consistent with early emergence of this apparent serotype switch strain. ST156, the identifier of the common multiresistant serotype 9V clone Spain 9V -3, together with single locus variant ST557, accounted for 5 serotype 19A isolates. ST236, the identifier of the common multidrug-resistant clone Taiwan 19F -14, together with its single locus variant ST271, accounted for 3 serotype 19A isolates. Table 2 presents pbp1a and pbp2b sequence data (under CC320) that are highly indicative of a serotype switch event that resulted in simultaneous changes in serotype and ␤-lactam resistance in the ST236 19A variant. ST292 accounted for 3 serotype 19A isolates and has only been associated with serotype 15A. ST338 is the identifier of Colombia 23F -26 and has been increasingly found among penicillin-intermediate type 23A isolates in the United States [22, 24] . Single 19A isolates of ST1797 and ST690 were observed, which were previously only reported among serotype 7C and serogroup 6 isolates, respectively [23, 24] .
Resistance to penicillin consistently predicted resistance to other antibiotic classes and was distributed among several different genetic complexes. Most penicillin-resistant strains were found within CC320 (table 2) . Within CC199, 13 of 313 isolates were penicillin resistant, and most were found among recently reported single locus variants of ST199 (figure 4). Remaining penicillin-resistant isolates were primarily found among clonal complexes highly related to clones recognized by the Pneumococcal Molecular Epidemiology Network (available at: http:// www.sph.emory.edu/PMEN/), including 12 of 13 CC1339 isolates (highly related to clone North Carolina 6A -23), all 7 CC81 isolates (Spain 23F -1), 5 of 8 CC156 isolates (Spain 
DISCUSSION
Since PCV7 was introduced in the United States in 2000, serotype 19A has emerged as the most common invasive serotype overall and accounts for the largest proportion of resistant invasive infections (figure 2). Among children aged Ͻ5 years, the group targeted for vaccination with PCV7, the incidence of IPD caused by serotype 19A increased Ͼ2.5-fold. Although the absolute increase in the incidence of IPD (6.7 cases per 100,000 population) was largest in this age group, the observed increase was small, compared with the overall decrease (nearly 80 cases per 100,000 population) during the same period [28] . Similarly, among adults, the increase in serotype 19A IPD was modest, compared with the reduction in incidence of IPD among adults that resulted from the indirect effects of vaccinating children [1, 2] . Still, the upward trend in the annual incidence of IPD caused by serotype 19A showed no signs of slowing during 2000 -2005 . We integrated population-based surveillance for IPD with genetic analysis of serotype 19A strains in an attempt to explain these changes.
A major concern in countries considering adoption of pneumococcal conjugate vaccines is that vaccine introduction will lead to the emergence of pneumococcal disease caused by non- vaccine serotypes (i.e., serotype replacement) [29] . However, our experience with serotype 19A suggests that several factors interact to produce conditions favorable to the emergence of nonvaccine serotypes. First, serotype 19A appears equally capable of causing invasive disease, nasopharyngeal colonization, and acute otitis media [30 -32] , a property not shared by most other non-PCV7 serotypes. Second, before the introduction of PCV7 in the United States, 19A was the ninth most common serotype that caused IPD in children aged Ͻ5 years, with only PCV7 types and PCV7-related type 6A being more common [33] . Another potential factor predisposing serotype 19A to become a predominant cause of IPD includes the commonness of 19A carriage during the prevaccine period, which is reflected by the relatively high percentage of IPD cases caused by this serotype rather than other non-PCV7 serotypes during the postvaccine period. Thus, serotype 19A was poised to fill the ecologic niche left by reduced numbers of PCV7 types [13, 30, 34] . Third, Ͼ60% of invasive 19A isolates described in our study and 25%-75% of 19A nasopharyngeal colonizers described in other studies were nonsusceptible to penicillin [13, 35] . Antibiotic nonsusceptibility provides an additional survival advantage for serotype 19A. Finally, PCV7 is not active against 19A [11, 36, 37] . Of the non-PCV7 serotypes identified in our surveillance areas, serotype 35B currently shares some of these same properties [13, 38] . Evaluation of the epidemiology of serotype 19A in other settings can also clarify the relationship between vaccine introduction and the emergence of nonvaccine serotypes. In Alaska, PCV7 was made available to all children in 2001, but serotype 19A was not evident as a major nasopharyngeal colonizer until 2004 [39] ; by 2006, serotype 19A had become an important cause of IPD [34] . Among Navajo children, some of whom began receiving PCV7 in 1997 [40] , the incidence of IPD caused by serotype 19A has not increased. The Bedouin population of southern Israel has seen a large increase in 19A despite the absence of PCV7 vaccination [41] . This increase appears to be attributable almost exclusively to 1 multidrug-resistant 19A clone with ST276 (which is within the fourth largest clonal complex from our study [ figure 4A] ). Conversely, in the neighboring Jewish population, where this clone has not been observed in association with any serotype, no increase in 19A has been observed. Finally, in the Republic of Korea, PCV7 was introduced in 2004, but IPD caused by 19A was increasing as early as 2000 [42] . The emergence of 19A in various populations, including our own, is likely a function of multiple and differing combinations of factors, including the baseline prevalences of 19A and of individual virulent pneumococcal clones, patterns of antibiotic use, and pneumococcal transmission frequency. Introduction of PCV7 into a population may be followed temporally by the emergence of non-PCV7 serotypes, but there are not sufficient data to implicate PCV7 as the only or even the most important factor among the many that may be involved.
When some of these factors do interact, they provide an ecological niche for certain clones to expand. The most striking example of a rapidly expanding 19A clonal complex is CC320. This highly antibiotic-resistant complex was undetected in extensive surveillance before PCV7 introduction [23] , has emerged disproportionately in ABCs sites under continuous surveillance, and has now been detected in all 10 surveillance sites. Furthermore, CC320 has increased Ͼ2-fold among children aged Ͻ2 years since our recent genotypic survey of 19A [5] , making it the fastest-growing 19A clonal complex in the United States. It is also evident that CC199 -the major 19A complex circulating before PCV7 implementation that was primarily penicillin intermediate or susceptible-is continuing to expand. However, despite its expansion, CC199 isolates comprise a smaller percentage of invasive 19A isolates because of the increase in CC320. This increase in the percentage of CC320 isolates relative to the percentage of CC199 isolates within serotype 19A is concordant with the observation that the percentage of penicillin-resistant isolates within serotype 19A was substantially greater in 2005, compared with 2003 and 2004 (figure 3A). Our surveillance system gathers no information on antecedent antibiotic exposure for individual cases of IPD. This limits our ability to determine the contribution of antibiotic use at the individual level to the increase in infections with resistant clones.
Our data also shed light on the role of capsular switching in the emergence of non-PCV7 serotypes [43] . There were several serotype 19A strains in this study that may have arisen through capsular switch events, including (but not restricted to) type 19A variants of sequence types 156, 236, 271, 292, 338, 690, 695, 557, 899, and 1797. Each of these sequence types has been solely associated with serotypes other than 19A and, with the exceptions of ST292 and ST1797, has been primarily associated with PCV7 serotypes. Although we did not detect CC320 serotype 19A isolates during extensive surveillance before PCV7 introduction, CC320 was common among serotype 19F strains and was detected in an invasive 19A isolate recovered from a child during 2001 [24] . The most frequent sequence type within CC320, ST320, is documented from a type 19A sputum isolate recovered in Korea during 2000 [20] . Of the 111 CC320 isolates in our study, only 3 were not penicillin resistant. Two of these 3 were the sole representatives of ST236, the typically highly resistant Taiwan 19F -14 clone. One possible explanation for the resistance phenotypes of these 2 ST236 isolates is that a penicillin-resistant ST236 serotype 19F recipient strain was cotransformed to the 19A serotype and to decreased penicillin resistance. Such an event is feasible because of the proximity of the type 19A capsular locus and the flanking pbp1a and pbp2x sequences [25, 44, 45] . Preliminary sequencing data from these ST236 19A variants, as well as from the putative cps locus donor and recipient, supports this contention (table 2). ST695 identifies the major US invasive serotype 4 clone [23, 24] , and serotype 19A variants of ST695 appear to be a compelling example of a successful capsular switch event [25, 45] . Serotype 4 isolates of ST695 have uniformly displayed complete penicillin susceptibility (MIC, 0.03 g/mL), whereas all of the ST695 serotype 117 (37) 183 (58) 13 (4.2) . . . . . . Eight Pen-resistant CC199 isolates contained divergent ddl alleles, presumably because of "hitchhiking" with Pen resistance-conferring mosaic derivatives of pbp2b [22] . A total of 78 CC199 isolates were Ery resistant, 2 of which were also Pen resistant. Of 64 Ery-resistant CC199 isolates tested for the presence of mef (mefA or erm (ermB or ermTR) determinants, 58 contained mef only, 3 contained erm only, and 3 isolates contained both mef and erm. The 6 isolates containing erm accounted for all 6 Clind-nonsusceptible CC199 isolates [5, 23, 24] . ST1936 is a descendant of ST199, which was first described in 2005 [18] . . . . CC320 was previously designated as CC271 [5, 24] . ST271 is the predicted founder of a 130 MLST type complex in the global database, whereas ST320 is the predicted founder of this 12 MLST type complex, when eBURST analysis is restricted to these serotype 19A isolates recovered in 2005. A total of 107 strains (96%) were Ery resistant, of which 95 (89%) were also resistant to Clind. Seventy-four of 82 CC322 isolates tested contained both ermB and mefA. sequence from the ST199 putative donor [25] and the 19A ST236 (putative progeny) isolates is identical and unique from all other currently known corresponding sequences (2 differences from the closest known match). (7) 29 (76) 9 ( . . . CC695 was previously known as CC247 [22] , which is the predicted founder of a 24 MLST type complex in the global database. ST695 is the predicted founder, based on our 2005 ABCs data (figure 4), and the most common ST among invasive serotype 4 isolates recovered in the US. This potential capsular switch event appears to have recently occurred between the major US serotype 4 strain (recipient) and ST199 19A (donor) [25] . . . . CC1339 was previously referred to as CC1296 [5] and is the predicted founder of this complex, based on data from our 2005 data set. All members are closely related to ST376, the identifier of multiresistant North Carolina 6A -23 and a common genotype among US invasive 6A isolates [23, 24] . All isolates were Ery resistant (12 were mefA positive, and 1 was mefA positive and ermB positive). ST1339 was initially found in ABCs from an invasive, multiresistant type 19A isolate recovered from a child in 2002 [24] . Twelve of these 13
isolates were recovered from Tennessee. upon all known MLST data. ST81 was documented from 3 invasive serotype 19A isolates recovered in Spain during 1990 and 1994 [20] . A serotype 19A SLV (ST634) of ST81 was recovered from a child in Georgia during 1999 [23] , and 5 additional type 19A isolates of this complex were detected in previous ABCs studies conducted after heptavalent pneumococcal conjugate vaccine introduction [5, 24] . All 7 isolates were resistant to Pen, Ery, and Clind (5 were ermB positive, and 2 were positive for ermB and mefA), and all were recovered in Tennessee. [23, 24] . ST338, the identifier of Columbia 23F -26, was found among previous 19A isolates recovered after heptavalent pneumococcal conjugate vaccine introduction [5] and was also found among type 23A
isolates [22] . ST2539 is a DLV of CSR 19A -11 [27] ; the isolate was also resistant to Ceph and Ery (ermB positive).
NOTE. Ceph, third-generation cephalosporins; Clind, clindamycin; DLV, double locus variant; Ery, erythromycin; Int, intermediately susceptible; Pen, penicillin; Res, resistant; SLV, single locus variant; Sus, susceptible; Tet, tetracycline; TMP-SMZ, trimethoprim-sulfamethoxazole; US, United States.
19A variants were either intermediately susceptible to penicillin or had penicillin MICs at the upper end of the susceptible range (i.e., 0.06 g/mL). Because serotype 19A ST199 strains were prevalent before and after vaccine implementation and were generally nonsusceptible to penicillin, it was possible that a ST199 strain might be the donor of the capsular locus. Sequence analysis of the cps flanking regions (including pbp2x and pbp1a) from putative serotype 19A donors, serotype 4 ST695 recipients (the genotype into which the 19A capsular locus recombined), and all ST695 19A progeny collected through 2005 demonstrated, for the first time, that the capsular locus and both adjacent penicillin-binding proteins were transferred in a single recombinational event, which also resulted in penicillin nonsusceptibility [25] . It is also interesting that examination of the cps-flanking regions among the remaining 6 CC695 serotype 19A isolates indicates 2 additional independent serotype switch recombination events [25] .
An advantage of our investigation is that it combines epidemiologic data from an active, population-based surveillance system with extensive genotyping of isolates collected from wellcharacterized cases. This allows us to compare our rates of IPD to those of other investigators in other settings [45] [46] [47] , while simultaneously providing potential insights into why rates of IPD have evolved as they have. Continued genotypic surveillance of this nature will allow us to detect and track strains that have acquired the selective advantages required for persistence and expansion and may help us to understand the role that clonal features play in predicting the emergence of non-PCV7 serotypes.
This work and the work of others has important implications for future prevention strategies [34, [45] [46] [47] . Future pneumococcal conjugate vaccines intended for use in the United States should target serotype 19A through its inclusion in their formulations or through cross-protection from other serotypes, such as 19F [9] . Integration of prospective, population-based surveillance for IPD with serotyping, susceptibility testing, and genotypic characterization can help to elucidate the emergence of nonvaccine serotypes following conjugate vaccine introduction.
